More than $582 Billion in New U.S. Investment Since 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
The world’s pharmaceutical companies are stepping up their investments in America.
We Work For Health’s tracking tool, the U.S. Biopharma Investment Watch, is documenting these developments and providing visibility into the sector's robust expansion and critical role in securing America's position as the global leader in health care innovation. Since January 2025, companies have committed to investing more than $582 billion to bolster U.S. research and development, expand manufacturing, and create jobs across the country.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, powering high-skill positions for scientists and engineers, construction and production support roles, and millions of jobs for the communities surrounding the facilities. This builds upon more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
The tracker reflects the sector’s commitment to preserving American leadership in the life sciences, as China continues a coordinated campaign to overtake it.
1,488%
increase in announced U.S. facility investments in 2025 vs 2024
Tens of Thousands
of new construction jobs across America
Faster delivery
of breakthrough medicines to U.S. patients
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
U.S. Biopharma Investment Watch
Legend:
Announcement date
Company
Investment amount
Investment location(s)
Nov 19, 2025
Novartis
Unspecified
Durham-NC, Morrisville-NC
A new site in Durham featuring two facilities dedicated to manufacturing biologics and sterile packaging. Also an expansion of an existing Durham facility with the added capability to support sterile filling of biologics into syringes and vials.
A new site in Morrisville with one facility for the production of solid dosage tablets and capsules, including packaging.
These investments are expected to create 700 new jobs in North Carolina by 2030 and support more than 3,000 indirect jobs across the Novartis U.S. supply chain.
Part of a larger, previously announced $23 billion company investment.
Oct 29, 2025
Eli Lilly
$1.2 billion
Carolina-PR
Expansion and modernization of the Lilly del Caribe manufacturing site to support the company's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. The project will generate an estimated 1,000 construction jobs and 100 additional high-tech manufacturing positions.
Part of a larger, previously announced $27 billion company investment.
Oct 20, 2025
Merck
$70 billion
Unspecified location
Investment in U.S. capital projects, research and development to drive long-term growth and fortify America’s position as a global leader in drug innovation.
Amount includes previously announced projects in Rahway, NJ, Wilmington, DE, and Elkton, VA, which represent an estimated $7.5 billion commitment. The company also disclosed $3 billion in planned biologics and small molecule manufacturing sites and capabilities in the U.S., projected to create 800 additional jobs.
Oct 20, 2025
Merck
$3 billion
Elkton–VA
Broke ground on a project to enhance an existing site with a 400,000-square-foot Center of Excellence for pharmaceutical manufacturing. The facility will support small molecule manufacturing and testing and will potentially create more than 500 full-time roles as well as 8,000 construction jobs.
Part of a $70 billion U.S. investment plan.
Oct 10, 2025
Ypsomed
$248 million
Holly Springs-NC
A 15,000-square-meter factory that will be the Switzerland-based company’s first manufacturing facility in the United States. The facility will supply products solely for the U.S. market and is expected to create around 100 new jobs, with the goal of expanding the workforce to about 200 in the coming years as demand increases.
Oct 9, 2025
AstraZeneca
$4.5 billion
Albemarle-VA
A new manufacturing facility that is scheduled to increase output of various medicines, including cancer treatments, once operational within the next five to six years. Will create 3,600 direct and indirect jobs, including 3,000 tied to the project's construction phase.
Part of a larger, previously announced $50 billion investment.
Sep 23, 2025
Eli Lilly
$6.5 billion
Houston-TX
New next-generation API manufacturing facility that will focus on small molecule medicines across several therapeutic areas, including cardiometabolic health, immunology, neuroscience and oncology. Scheduled to be operational within five years, the facility will create 615 permanent high-wage jobs plus 4,000 construction jobs.
Part of a larger, previously announced $27 billion company investment.
No entries found matching your criteria. Please modify your filters.
Methodology
All investments data comes from publicly available resources. Investments may span across multiple states and, therefore, are reflected on each state page. Investment locations will be updated once specified.
-
Jobs data source: WWFH “in the states” page
-
Labor hours data source: PILMA jobs report page